Aadi Bioscience Charts a New Course with Strategic Pivot

Shares of Aadi Bioscience have demonstrated stability as the biotechnology firm executes a fundamental strategic overhaul. The company is shifting its focus from a marketed drug to building a preclinical pipeline centered on antibody-drug conjugates (ADCs). This redirection was facilitated by a series of financial maneuvers designed to secure the company’s liquidity well into the latter half of this decade.

A Three-Part Strategic Shift

The corporate transformation is built upon three pivotal actions, fundamentally altering Aadi’s business model:

1. Divestment of Commercial Asset: Aadi sold its commercialized drug, FYARRO®, to Kaken Pharmaceuticals for $100 million in cash.
2. Pipeline Acquisition: Concurrently, the company in-licensed an exclusive portfolio of three preclinical ADC candidates from WuXi Biologics and Hangzhou DAC. This agreement involves a $44 million upfront payment, with provisions for significant future milestone payments and royalties on sales.
3. Capital Infusion: To fund its new strategic direction, Aadi completed a private investment in public equity (PIPE) financing, raising approximately $100 million.

Collectively, these steps signify a definitive transition from a commercial-stage entity to a research-focused biotechnology company.

Should investors sell immediately? Or is it worth buying Aadi Bioscience?

Financial Runway and Catalysts

The combined proceeds from the asset sale and the equity financing are projected to extend Aadi Bioscience’s financial resources deep into 2028. These funds are earmarked for advancing the newly acquired ADC candidates, with initial clinical data anticipated within the coming years.

This strategic pivot follows a period of challenge. In the third quarter of 2024, prior to the restructuring, the company reported a net loss of $12.5 million on FYARRO® revenue of $7.2 million. The urgency for change was accelerated in August 2024 by a setback in a Phase 2 trial, which led to the termination of that specific development program and significant workforce reductions.

The company’s renewed dedication to oncology research was further emphasized by the appointment of David Dornan as Chief Scientific Officer in February 2025. Market valuation of Aadi’s stock is now primarily based on the potential of its recently established ADC pipeline, marking a fresh chapter for the firm.